U.S. flag

An official website of the United States government

NM_001048174.2(MUTYH):c.1192C>T (p.Arg398Cys) AND not specified

Germline classification:
Conflicting interpretations of pathogenicity (5 submissions)
Last evaluated:
Jul 31, 2024
Review status:
criteria provided, conflicting classifications
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000212715.36

Allele description [Variation Report for NM_001048174.2(MUTYH):c.1192C>T (p.Arg398Cys)]

NM_001048174.2(MUTYH):c.1192C>T (p.Arg398Cys)

Gene:
MUTYH:mutY DNA glycosylase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
1p34.1
Genomic location:
Preferred name:
NM_001048174.2(MUTYH):c.1192C>T (p.Arg398Cys)
Other names:
p.R426C:CGT>TGT
HGVS:
  • NC_000001.11:g.45331467G>A
  • NG_008189.1:g.14004C>T
  • NM_001048171.2:c.1192C>T
  • NM_001048172.2:c.1195C>T
  • NM_001048173.2:c.1192C>T
  • NM_001048174.2:c.1192C>TMANE SELECT
  • NM_001128425.2:c.1276C>T
  • NM_001293190.2:c.1237C>T
  • NM_001293191.2:c.1225C>T
  • NM_001293192.2:c.916C>T
  • NM_001293195.2:c.1192C>T
  • NM_001293196.2:c.916C>T
  • NM_001350650.2:c.847C>T
  • NM_001350651.2:c.847C>T
  • NM_012222.3:c.1267C>T
  • NP_001041636.1:p.Arg412Cys
  • NP_001041636.2:p.Arg398Cys
  • NP_001041637.1:p.Arg399Cys
  • NP_001041638.1:p.Arg398Cys
  • NP_001041639.1:p.Arg398Cys
  • NP_001121897.1:p.Arg426Cys
  • NP_001121897.1:p.Arg426Cys
  • NP_001280119.1:p.Arg413Cys
  • NP_001280120.1:p.Arg409Cys
  • NP_001280121.1:p.Arg306Cys
  • NP_001280124.1:p.Arg398Cys
  • NP_001280125.1:p.Arg306Cys
  • NP_001337579.1:p.Arg283Cys
  • NP_001337580.1:p.Arg283Cys
  • NP_036354.1:p.Arg423Cys
  • NP_036354.1:p.Arg423Cys
  • LRG_220t1:c.1276C>T
  • LRG_220:g.14004C>T
  • LRG_220p1:p.Arg426Cys
  • NC_000001.10:g.45797139G>A
  • NM_001048171.1:c.1234C>T
  • NM_001048174.1:c.1192C>T
  • NM_001048174.2:c.1192C>T
  • NM_001128425.1:c.1276C>T
  • NM_012222.2:c.1267C>T
  • NR_146882.2:n.1420C>T
  • NR_146883.2:n.1269C>T
  • p.R426C
Protein change:
R283C
Links:
dbSNP: rs150792276
NCBI 1000 Genomes Browser:
rs150792276
Molecular consequence:
  • NM_001048171.2:c.1192C>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001048172.2:c.1195C>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001048173.2:c.1192C>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001048174.2:c.1192C>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001128425.2:c.1276C>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001293190.2:c.1237C>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001293191.2:c.1225C>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001293192.2:c.916C>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001293195.2:c.1192C>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001293196.2:c.916C>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001350650.2:c.847C>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_001350651.2:c.847C>T - missense variant - [Sequence Ontology: SO:0001583]
  • NM_012222.3:c.1267C>T - missense variant - [Sequence Ontology: SO:0001583]
  • NR_146882.2:n.1420C>T - non-coding transcript variant - [Sequence Ontology: SO:0001619]
  • NR_146883.2:n.1269C>T - non-coding transcript variant - [Sequence Ontology: SO:0001619]
Observations:
5

Condition(s)

Synonyms:
AllHighlyPenetrant
Identifiers:
MedGen: CN169374

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV000697674Women's Health and Genetics/Laboratory Corporation of America, LabCorp
criteria provided, single submitter

(LabCorp Variant Classification Summary - May 2015)
Likely benign
(Jun 24, 2024)
germlineclinical testing

PubMed (27)
[See all records that cite these PMIDs]

Citation Link,

SCV000711723Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine
criteria provided, single submitter

(LMM Criteria)
Uncertain significance
(Jan 11, 2017)
germlineclinical testing

PubMed (16)
[See all records that cite these PMIDs]

SCV000885747ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
criteria provided, single submitter

(ARUP Molecular Germline Variant Investigation Process)
Likely benign
(Aug 29, 2018)
germlineclinical testing

Citation Link,

SCV002067654Genetic Services Laboratory, University of Chicago
criteria provided, single submitter

(ACMG Guidelines, 2015)
Uncertain significance
(Jan 4, 2022)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

SCV002552418Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital
criteria provided, single submitter

(ACMG Guidelines, 2015)
Uncertain significance
(Jul 31, 2024)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlinenonot providednot providednot providednot providednot providedclinical testing
not providedgermlinenot provided55not providednot providednot providedclinical testing
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Clinical and molecular features of attenuated adenomatous polyposis in northern Italy.

de Leon MP, Urso ED, Pucciarelli S, Agostini M, Nitti D, Roncucci L, Benatti P, Pedroni M, Kaleci S, Balsamo A, Laudi C, Di Gregorio C, Viel A, Rossi G, Venesio T.

Tech Coloproctol. 2013 Feb;17(1):79-87. doi: 10.1007/s10151-012-0887-5. Epub 2012 Sep 14.

PubMed [citation]
PMID:
22976915

Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort.

Ring KL, Bruegl AS, Allen BA, Elkin EP, Singh N, Hartman AR, Daniels MS, Broaddus RR.

Mod Pathol. 2016 Nov;29(11):1381-1389. doi: 10.1038/modpathol.2016.135. Epub 2016 Jul 22.

PubMed [citation]
PMID:
27443514
PMCID:
PMC5541389
See all PubMed Citations (33)

Details of each submission

From Women's Health and Genetics/Laboratory Corporation of America, LabCorp, SCV000697674.7

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (27)

Description

Variant summary: MUTYH c.1276C>T (p.Arg426Cys) results in a non-conservative amino acid change located in the NUDIX hydrolase domain (IPR000086) of the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00081 in 252980 control chromosomes, predominantly at a frequency of 0.0014 within the Non-Finnish European subpopulation in the gnomAD database, including 1 homozygotes. This frequency is not significantly higher than estimated for a pathogenic variant in MUTYH causing MUTYH-Associated Polyposis (0.00081 vs 0.0046), allowing no conclusion about variant significance. c.1276C>T has been reported in multiple FAP or attenuated FAP patients in monoallelic state (e.g. Aceto_2005, Aretz_2006, de Lyon_2013, Ricci_2017, Sulova_2009). Furthermore, it has been reported with other pathogenic MUTYH variants in biallelic patients affected with synchronous/metachronous polyps (Lopez-Villar_2010) and colorectal cancer (e.g. De Rycke 2017, Yurgelun 2017). In some of these reports, it was classified as a VUS in settings of multigene cancer panel testing. Additional reports of the variant in individuals with a personal and/or family history of colorectal cancer, HBOC, lung and endometrial cancer have also been published (e.g. Fleischmann_2004, Ricci_2016, Ring_2016, Tung_2016, Martin-Morales_2018, Rizzolo_2018, Oliver_2019, Lin_2019, Tsaousis_2019, Grasel_2020, Pope_2021, Sahin_2022). These data do not allow any conclusion about variant significance. Multiple co-occurrences with other pathogenic variant(s) have been observed at our laboratory (BRCA2 c.4647_4650delAGAG , p.Lys1549fsX18 ; APC c.2161_2170delGGAAGTGCTG, p.Gly721fsX3; MSH6 c.3013C>T, p.Arg1005X; PALB2 c.2386G>T, p.Gly796X), providing supporting evidence for a benign role. At least one publication reports experimental evidence evaluating an impact on protein function. These results showed no damaging effect of this variant as evidenced by comparable function to wild-type in terms of suppression of spontaneous mutations (Komine_2015). The following publications have been ascertained in the context of this evaluation (PMID: 22703879, 25820570, 16134147, 16557584, 19531215, 24470512, 20687945, 17524638, 14991577, 26976419, 22976915, 27443514, 28135145, 28944238, 30256826, 30151275, 27829682, 30564557, 30850667, 31159747, 31921681, 31422818, 33383211, 33134171, 35089076, 35430768, 35628513). ClinVar contains an entry for this variant (Variation ID: 41753). Based on the evidence outlined above, the variant was classified as likely benign.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine, SCV000711723.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not provided5not providednot providedclinical testing PubMed (16)

Description

The p.Arg426Cys variant in MUTYH has been reported in at > 8 individuals with co lorectal cancer (Aceto 2005, Aretz 2006, Sulova 2007, Gomez-Fernadez 2009, Lopez -Villar 2010, Guarinos 2014, Yurgelun 2015, Ricci 2017), 2 individuals with brea st cancer (Tung 2016), 1 individual with lung cancer (Al-Tassan 2004) and has a lso been reported by other clinical laboratories in ClinVar (Variation ID 41753) . All individuals reported in the literature were heterozygous and did not carry a second MUTYH variant. This variant has also been identified in 0.1% (184/1266 06) of European chromosomes by gnomAD (http://gnomad.broadinstitute.org). Althou gh this variant has been seen in the general population, its frequency is not hi gh enough to rule out a pathogenic role. In vitro functional studies provide som e evidence that the p.Arg426Cys variant may not impact protein function (Komine 2015) and computational prediction tools and conservation analysis suggest that the p.Arg426Cys variant may not impact the protein, though this information is n ot predictive enough to rule out pathogenicity. In summary, the clinical signifi cance of the p.Arg426Cys variant is uncertain. ACMG/AMP Criteria applied: BP4.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlinenot providednot providednot providednot provided5not provided5not provided

From ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories, SCV000885747.2

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From Genetic Services Laboratory, University of Chicago, SCV002067654.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)

Description

DNA sequence analysis of the MUTYH gene demonstrated a sequence change, c.1276C>T, in exon 13 that results in an amino acid change, p.Arg426Cys. This sequence change has been described in the gnomAD database with a frequency of 0.15% in the non-Finnish European sub-population (dbSNP rs150792276). The p.Arg426Cys change affects a poorly conserved amino acid residue located in a domain of the MUTYH protein that is not known to be functional. In-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL) provide contradictory results for the p.Arg426Cys substitution. The p.Arg426Cys sequence change has been reported in the heterozygous state in multiple individuals with colorectal cancer (PMIDs: 16134147, 16557584, 17524638, 19531215, 20687945, 24470512, 25980754), two individuals with breast cancer (PMID: 26976419), and one individual with lung cancer (PMID: 14579148). Functional studies using a yeast complementation assay demonstrated that MUTYH p.Arg426Cys had base excision repair activity similar to wild-type (PMID: 25820570). Due to these contrasting evidences, the clinical significance of the p.Arg426Cys change remains unknown at this time.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlinenonot providednot providednot providednot providednot providednot providednot provided

From Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, SCV002552418.5

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Nov 3, 2024